Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2005-05-10
2009-10-20
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S141100, C424S143100, C424S144100, C424S152100, C424S153100, C424S172100, C424S173100, C530S387100, C530S387300, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750
Reexamination Certificate
active
07604800
ABSTRACT:
Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.
REFERENCES:
patent: 5378464 (1995-01-01), McEver
patent: 5618785 (1997-04-01), Heavner et al.
patent: 5709859 (1998-01-01), Aruffo et al.
patent: 5710123 (1998-01-01), Heavner et al.
patent: 5808025 (1998-09-01), Tedder et al.
patent: 5827817 (1998-10-01), Larsen et al.
patent: 5834425 (1998-11-01), Tedder et al.
patent: 5840679 (1998-11-01), Larsen et al.
patent: 5843707 (1998-12-01), Larsen et al.
patent: 5852175 (1998-12-01), Cummings et al.
patent: 5972625 (1999-10-01), Rosen et al.
patent: 6056956 (2000-05-01), Cobbold et al.
patent: 6124267 (2000-09-01), McEver et al.
patent: 6309639 (2001-10-01), Cummings et al.
patent: 6348581 (2002-02-01), Anderson et al.
patent: 6667036 (2003-12-01), Cummings et al.
patent: 6884619 (2005-04-01), Hockfield et al.
patent: 2002/0164336 (2002-11-01), Harrison et al.
patent: 2003/0049252 (2003-03-01), Lin et al.
patent: 2004/0001839 (2004-01-01), Levanon et al.
patent: 2004/0002450 (2004-01-01), Lazarovits et al.
patent: WO 97/06176 (1997-02-01), None
patent: WO 00/25808 (2000-05-01), None
patent: WO 03/013603 (2003-02-01), None
Rudikoff et al. Proc Natl Acad Sci USA 79: 1979-1983,1982.
Colman, Research in Immunology 145: 33-36, 1994.
Battistini, et al. “CD8+ T cells from 1-37 patients with acute multiple sclerosis display selective increase of adhesiveness in brain venules: A critical role for P-selectin glycoprotein ligand-1.”Blood, vol. 101, No. 12, 4775-4782 (Jun. 15, 2003).
Beckwith et al., “The Protein Product of the Proto-oncogene c-cbl Forms a Complex With Phosphatidylinositol 3-Kinase p85 and CID 19 in Anti-IgM Stimulated Human B-Lymphoma Cells,”Blood88(9):3502-3507, (1996).
Besnault et al., “B Cell Receptor Cross-Linking Triggers a Caspase-8-Dependent Apoptotic Pathway That Is Independent of the Death Effector Domain of Fas-Associated Death Domain Protein,”J. Immunol., 167:733-740, (2001).
Borges et al., “P-Selectin Glycoprotein Ligand-1 (PSGL-1) on T Helper 1 but Not on T Helper 2 Cells Binds to P-Selectin and Supports Migration into Inflamed Skin,”J. Exp. Med. 185(3):573-578 (Feb. 3, 1997).
Borges et al., “The Binding of T Cell-expressed P-selectin Glycoprotein Ligand-1 to E- and P-selectin Is Differentially Regulated,”J. Biol. Chem. 272(45):28786-28792 (Nov. 7, 1997).
Diacovo, et al. “Interactions of human alpha/beta and gamma/delta T lymphocyte subsets in shear flow with E-seelctin and P-selectin.”J. Exp. Med., vol. 183, 1193-1203 (Mar. 1996).
Dimitroff, et al. “Glycosylation-dependent inhibition of cutaneous lymphocyte-associated antigen expression: Implications in modulating lymphocyte migration to skin.”Blood, vol. 101, No. 2, 602-610 (Jan. 15, 2003).
Evangelista et al., “Platelet/Polymorphonuclear Leukocyte Interaction: P-Selectin Triggers Protein-Tyrosine Phosphorylation-Dependent CD11b/CD 18 Adhesion: Role ofPSGL-1 as a Signaling Molecule,”Blood93(3):876-885 (Feb. 1, 1999).
Faraday et al., “Leukocytes Can Enhance Platelet-mediated Aggregation and Thromboxane Release via Interaction of P-selectin Glycoprotein Ligand 1 with P-selectin,”Anesthesiology94(1):145-151 (Jan. 2001).).
Frenette et al., “P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Expressed on Platelets and Can Mediate Platelet-Endothelial Interactions In Vivo,”J. Exp. Med. 191(8):1413-1422 (Apr. 17, 2000).
Fuhlbrigge et al., “Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells,”Nature389:978-981 (Oct. 1997).
Herron MJ et al., Intracellular parasitism by the human granulocytic ehrlichiosis bacterium through the P-selectin ligand, PSGL-1.Science. Jun. 2, 2000;288(5471):1653-6.
Hirata et al., “P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is a Physiological Ligand for E-Selectin in Mediating T Helper 1 Lymphocyte Migration,”J. Exp. Med. 192(11):1669-1675 (Dec. 4, 2000).
Hirose et al., “A functional epitope on P-selectin that supports binding of P-selectin to P-selectin glycoprotein ligand-1 but not to sialyl Lewis X oligosaccharides,”Internatl. Immunol. 10(5):639-649 (Jan. 26, 1998).
Igarashi et al., “Telomerase Activity Is Induced in Human Peripheral B Lymphocytes by the Stimulation to Antigen Receptor,”Blood, 89(4):1299-1307, (1997).
Kaytes, et al. “P-selectin mediates 1-37 adhesion of the human melanoma cell line NKI-4: Identification of glycoprotein ligands.”Biochemistry, vol. 37, No. 29, 10514-10521 (Jul. 21, 1998).
Kieffer, et al. “Neutrophilis, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: Cutaneous lymphocyte antigen.”Biochem. Biophys. Res. Comm., vol. 285, No. 3, 577-587 (Jul. 20, 2001).
Laszik et al., “P-Selectin Glycoprotein Ligand-1 Is Broadly Expressed in Cells of Myeloid, Lymphoid, and Dendritic Lineage and in Some Nonhematopoietic Cells,”Blood88(8):3010-3021 (Oct. 15, 1996).
Levesque et al., “PSGL-1-Mediated Adhesion of Human Hematopoietic Progenitors to P-Selectin Results in Suppression of Hematooiesis,”Immunity11:369-378 (Sep. 1999).
Li et al., “Visualization of P-Selectin Glycoprotein Ligand-1 As A Highly Extended Molecule and Mapping of Protein Epitopes for Monoclonal Antibodies,”J. Biol.Chem. 271(11):6342-6348 (1996).
Moore et al., “P-Selectin Glycoprotein Ligand-1 Mediates Rolling of Human Neutrophils on P-Selectin,”J. Cell Biol. 128(4):661-671 (1995).
Sako D et al., Expression cloning of a functional glycoprotein ligand for P-selectin.Cell. Dec. 17, 1993;75(6):1179-86.
Shan et al., “Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies,”Blood, 91(5):1644-1652, (1998).
Snapp et al., “A Novel P-Selectin Glycoprotein Ligand-1 Monoclonal Antibody Recognizes an Epitope Within the Tyrosine Sulfate Motif of Human PSGL-1 and Blocks Recognition of Both P- and L-Selectin,”Blood91(1):154-164 (Jan. 1, 1998).
Stockmeyer et al., “Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells,”J. Immunol., 171:5124-5129, (2003).
Trembleau, et al., “Pancreas-Infiltrating Th1 Cells and Diabetes Develop in IL-12 Deficient Nonobese Diabetic Mice,”J. Immunol. 163:2960-2968 1999).
Vachino G et al., P-selectin glycoprotein ligand-1 is the major counter-receptor for P-selectin on stimulated T cells and is widely distributed in non-functional form on many lymphocytic cells.J. Biol Chem. Sep. 15, 1995;270(37):21966-74.
Veldman GM et al., Genomic organization and chromosomal localization of the gene encoding human P-selectin glycoprotein ligand.J Biol Chem. Jul. 7, 1995;270(27):16470-5.
Wing et al., “Mechanism of First-Dose Cytokine-Release Syndrome by CAMPATH 1-H: Involvement of CD16 (FcyRlll) and CD11a/CD18 (LFA-1) on NK Cells,”J. Clin. Invest. 98(12):2819-2826 (1996).
Woltmann, et al. “Interleukin-13 induces PSGL-1/P-selectin-dependent adhesion of eosinophils, but not neutrophils, to human umbilical vein endothelial cells under flow.”Blood, vol. 95, No. 10, 3146-3152 (May 15, 2000).
Wu et al., “Role of P-Selectin and Anti-P-Selectin Monoclonal Antibody in Apoptosis During Hepatic/Renal Ischemia Reperfusion Injury,”World J. Gastroentero6(2):244-247 (2000).
Yago et al., “IL-12 Promotes the Adhesion of NK Cells to Endothelial Selectins Under Flow Conditions,”J. Immunol. 161:1140-1145 (1998).
Yang et al., “Targeted Gene Disruption Demonstrates That P-Selectin Glycoprotein Ligand 1 (PSGL-1) Is Required for P-Selectin-mediated but Not E-Selectin-mediated Neutrophil Rolling and Migration,”J. Exp. Med. 190(12):1769-1782 (De
Chang Chung Nan
Chen Pei-Jiun
Huang Chiu-Chen
Lin Rong-Hwa
AbGenomics Coöperatief U.A.
Gambel Phillip
Wolf Greenfield & Sacks P.C.
LandOfFree
Anti-PSGL-1 antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-PSGL-1 antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-PSGL-1 antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4088177